Nanobody-based products as research and diagnostic tools

Trends in Biotechnology

Volumn 32, Issue 5, 2014, Pages 263-270

  De Meyer, Thomas ^a,b   Muyldermans, Serge ^a,c   Depicker, Ann ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Antibody fragment; GFP binding protein; Nanobody; Plant production platform; Recombinant protein production; Yeast production platform

Indexed keywords

ANTIBODIES; DIAGNOSTIC PRODUCTS; RECOMBINANT PROTEINS; RESEARCH;

ANTIBODY FRAGMENT; FUNDAMENTAL RESEARCH; HEAVY-CHAIN ANTIBODIES; MULTIPLE APPLICATIONS; NANOBODY; RECOMBINANT PROTEIN PRODUCTIONS; SERENDIPITOUS DISCOVERY; YEAST PRODUCTION;

PRODUCTION PLATFORMS;

BIOLOGICAL PRODUCT; NANOBODY;

DIAGNOSTIC USE; HUMAN; MEDICAL RESEARCH; PROCEDURES;

BIOLOGICAL PRODUCTS; BIOMEDICAL RESEARCH; HUMANS; SINGLE-DOMAIN ANTIBODIES;

EID: 84899473717     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2014.03.001     Document Type: Review

References (93)

1. Pucca M.B., et al. Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals. Braz. J. Pharm. Sci. 2011, 47:31-39.
2. Teillaud J.L. From whole monoclonal antibodies to single domain antibodies: think small. Methods Mol. Biol. 2012, 911:3-13.
3. Lauwereys M., et al. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J. 1998, 17:3512-3520.
4. De Genst E., et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:4586-4591.
5. Rothbauer U., et al. Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat. Methods 2006, 3:887-889.
6. Zolghadr K., et al. Case study on live cell apoptosis-assay using lamin-chromobody cell-lines for high-content analysis. Methods Mol. Biol. 2012, 911:569-575.
7. Helma J., et al. Direct and dynamic detection of HIV-1 in living cells. PLoS ONE 2012, 7:e50026.
8. Ries J., et al. A simple, versatile method for GFP-based super-resolution microscopy via nanobodies. Nat. Methods 2012, 9:582-584.
9. Leduc C., et al. A highly specific gold nanoprobe for live-cell single-molecule imaging. Nano Lett. 2013, 13:1489-1494.
10. Herce H.D., et al. Visualization and targeted disruption of protein interactions in living cells. Nat. Commun. 2013, 4:2660.
11. Klooster R., et al. Improved anti-IgG and HSA affinity ligands: clinical application of VHH antibody technology. J. Immunol. Methods 2007, 324:1-12.
12. Klooster R., et al. Selection and characterization of KDEL-specific VHH antibody fragments and their application in the study of ER resident protein expression. J. Immunol. Methods 2009, 342:1-12.
13. Rothbauer U., et al. A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins. Mol. Cell. Proteomics 2008, 7:282-289.
14. Nguyen-Duc T., et al. Nanobody(R)-based chromatin immunoprecipitation/micro-array analysis for genome-wide identification of transcription factor DNA binding sites. Nucleic Acids Res. 2013, 41:e59.
15. Pollithy A., et al. Magnetosome expression of functional camelid antibody fragments (nanobodies) in Magnetospirillum gryphiswaldense. Appl. Environ. Microbiol. 2011, 77:6165-6171.
16. Schornack S., et al. Protein mislocalization in plant cells using a GFP-binding chromobody. Plant J. 2009, 60:744-754.
17. Jobling S.A., et al. Immunomodulation of enzyme function in plants by single-domain antibody fragments. Nat. Biotechnol. 2003, 21:77-80.
18. Caussinus E., et al. Fluorescent fusion protein knockout mediated by anti-GFP nanobody. Nat. Struct. Mol. Biol. 2012, 19:117-121.
19. Caussinus E., et al. Protein knockouts in living eukaryotes using deGradFP and green fluorescent protein fusion targets. Curr. Protoc. Protein Sci. 2013, 73. 30.2.1-30.2.13.
20. Kirchhofer A., et al. Modulation of protein properties in living cells using nanobodies. Nat. Struct. Mol. Biol. 2010, 17:133-138.
21. Tang J.C., et al. A nanobody-based system using fluorescent proteins as scaffolds for cell-specific gene manipulation. Cell 2013, 154:928-939.
22. 2 adrenoceptor. Nature 2011, 469:175-180.
23. Domanska K., et al. Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic beta 2-microglobulin variant. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:1314-1319.
24. Abskharon R.N., et al. Probing the N-terminal beta-sheet conversion in the crystal structure of the human prion protein bound to a nanobody. J. Am. Chem. Soc. 2014, 136:937-944.
25. Lam A.Y., et al. Nanobody-aided structure determination of the EpsI:EpsJ pseudopilin heterodimer from Vibrio vulnificus. J. Struct. Biol. 2009, 166:8-15.
26. Korotkov K.V., et al. Crystal structure of the N-terminal domain of the secretin GspD from ETEC determined with the assistance of a nanobody. Structure 2009, 17:255-265.
27. Loris R., et al. Crystal structure of the intrinsically flexible addiction antidote MazE. J. Biol. Chem. 2003, 278:28252-28257.
28. Saerens D., et al. Antibody fragments as probe in biosensor development. Sensors 2008, 8:4669-4686.
29. Saerens D., et al. Engineering camel single-domain antibodies and immobilization chemistry for human prostate-specific antigen sensing. Anal. Chem. 2005, 77:7547-7555.
30. Harmsen M.M., Fijten H.P.D. Improved functional immobilization of llama single-domain antibody fragments to polystyrene surfaces using small peptides. J. Immunoassay Immunochem. 2012, 33:234-251.
31. Even-Desrumeaux K., et al. Strong and oriented immobilization of single domain antibodies from crude bacterial lysates for high-throughput compatible cost-effective antibody array generation. Mol. Biosyst. 2010, 6:2241-2248.
32. Abbady A.Q., et al. Chaperonin GroEL a Brucella immunodominant antigen identified using nanobody and MALDI-TOF-MS technologies. Vet. Immunol. Immunopathol. 2012, 146:254-263.
33. Deckers N., et al. Nanobodies, a promising tool for species-specific diagnosis of Taenia solium cysticercosis. Int. J. Parasit. 2009, 39:625-633.
34. Saerens D., et al. Parallel selection of multiple anti-infectome nanobodies without access to purified antigens. J. Immunol. Methods 2008, 329:138-150.
35. Habib I., et al. VHH (nanobody) directed against human glycophorin A: a tool for autologous red cell agglutination assays. Anal. Biochem. 2013, 438:82-89.
36. Ladenson R.C., et al. Isolation and characterization of a thermally stable recombinant anti-caffeine heavy-chain antibody fragment. Anal. Chem. 2006, 78:4501-4508.
37. Vaneycken I., et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J. 2011, 25:2433-2446.
38. Huang L., et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol. Imaging Biol. 2008, 10:167-175.
39. Broisat A., et al. Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions. Circ. Res. 2012, 110:927-937.
40. Movahedi K., et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. 2012, 72:4165-4177.
41. De Groeve K., et al. Nanobodies as tools for in vivo imaging of specific immune cell types. J. Nucl. Med. 2010, 51:782-789.
42. Vaneycken I., et al. In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. J. Nucl. Med. 2010, 51:1099-1106.
43. Kijanka M., et al. Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery. Eur. J. Nucl. Med. Mol. Imaging 2013, 40:1718-1729.
44. Oliveira S., et al. Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Mol. Imaging 2012, 11:33-46.
45. Conrath K.E., et al. β-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob. Agents Chemother. 2001, 45:2807-2812.
46. De Meyer T., et al. Generation of VHH antibodies against the Arabidopsis thaliana seed storage proteins. Plant Mol. Biol. 2014, 10.1007/s11103-013-0118-0.
47. Garaicoechea L., et al. Llama-derived single-chain antibody fragments directed to rotavirus VP6 protein possess broad neutralizing activity in vitro and confer protection against diarrhea in mice. J. Virol. 2008, 82:9753-9764.
48. Hussack G., et al. Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J. Biol. Chem. 2011, 286:8961-8976.
49. Franco E.J., et al. Production and characterization of a genetically engineered anti-caffeine camelid antibody and its use in immunoaffinity chromatography. J. Chromatogr. B 2010, 878:177-186.
50. Zarschler K., et al. High-yield production of functional soluble single-domain antibodies in the cytoplasm of Escherichia coli. Microb. Cell Fact. 2013, 12:97.
51. Li T.F., et al. Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging. FASEB J. 2012, 26:3969-3979.
52. Järviluoma A., et al. High-affinity target binding engineered via fusion of a single-domain antibody fragment with a ligand-tailored SH3 domain. PLoS ONE 2012, 7:e40331.
53. Saerens D., et al. Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. J. Mol. Biol. 2005, 352:597-607.
54. Olichon A., Surrey T. Selection of genetically encoded fluorescent single domain antibodies engineered for efficient expression in Escherichia coli. J. Biol. Chem. 2007, 282:36314-36320.
55. Joosten V., et al. Expression and production of llama variable heavy-chain antibody fragments (V(HH)s) by Aspergillus awamori. Appl. Microbiol. Biotechnol. 2005, 66:384-392.
56. Okazaki F., et al. Efficient heterologous expression and secretion in Aspergillus oryzae of a llama variable heavy-chain antibody fragment VHH against EGFR. Appl. Microbiol. Biotechnol. 2012, 96:81-88.
57. Gorlani A., et al. Antibody engineering reveals the important role of J segments in the production efficiency of llama single-domain antibodies in Saccharomyces cerevisiae. Protein Eng. Des. Sel. 2012, 25:39-46.
58. Thomassen Y.E., et al. Large-scale production of VHH antibody fragments by Saccharomyces cerevisiae. Enzyme Microb. Technol. 2002, 30:273-278.
59. Ezzine A., et al. Efficient expression of the anti-AahI' scorpion toxin nanobody under a new functional form in a Pichia pastoris system. Biotechnol. Appl. Biochem. 2012, 59:15-21.
60. Omidfar K., et al. Studies of thermostability in Camelus bactrianus (Bactrian camel) single-domain antibody specific for the mutant epidermal-growth-factor receptor expressed by Pichia. Biotechnol. Appl. Biochem. 2007, 46:41-49.
61. HH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J. Biotechnol. 2000, 78:11-21.
62. van de Laar T., et al. Increased heterologous protein production by Saccharomyces cerevisiae growing on ethanol as sole carbon source. Biotechnol. Bioeng. 2007, 96:483-494.
63. Iqbal U., et al. Kinetic analysis of novel mono- and multivalent VHH-fragments and their application for molecular imaging of brain tumours. Br. J. Pharmacol. 2010, 160:1016-1028.
64. Agrawal V., et al. Stable expression of chimeric heavy chain antibodies in CHO cells. Methods Mol. Biol. 2012, 911:287-303.
65. Zhang J.B., et al. Transient expression and purification of chimeric heavy chain antibodies. Protein Expr. Purif. 2009, 65:77-82.
66. Winichayakul S., et al. Head-to-tail fusions of camelid antibodies can be expressed in planta and bind in rumen fluid. Biotechnol. Appl. Biochem. 2009, 53:111-122.
67. De Buck S., et al. Fusion of an Fc chain to a VHH boosts the accumulation levels in Arabidopsis seeds. Plant Biotechnol. J. 2013, 11:1006-1016.
68. Ismaili A., et al. Production and characterization of anti-(mucin MUCI) single-domain antibody in tobacco (Nicotiana tabacum cultivar Xanthi). Biotechnol. Appl. Biochem. 2007, 47:11-19.
69. Rahbarizadeh F., et al. Over expression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris. Mol. Immunol. 2006, 43:426-435.
70. Teh Y.H.A., Kavanagh T.A. High-level expression of Camelid nanobodies in Nicotiana benthamiana. Transgenic Res. 2010, 19:575-586.
71. Lentz E.M., et al. Translational fusion and redirection to thylakoid lumen as strategies to improve the accumulation of a camelid antibody fragment in transplastomic tobacco. Planta 2012, 236:703-714.
72. Conrad U., et al. ELPylated anti-human TNF therapeutic single-domain antibodies for prevention of lethal septic shock. Plant Biotechnol. J. 2011, 9:22-31.
73. Virdi V., et al. Orally fed seeds producing designer IgAs protect weaned piglets against enterotoxigenic Escherichia coli infection. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:11809-11814.
74. Tokuhara D., et al. Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection. J. Clin. Invest. 2013, 123:3829-3838.
75. Julve J.M., et al. A coat-independent superinfection exclusion rapidly imposed in Nicotiana benthamiana cells by tobacco mosaic virus is not prevented by depletion of the movement protein. Plant Mol. Biol. 2013, 81:553-564.
76. Gomez-Sebastian S., et al. Rotavirus A-specific single-domain antibodies produced in baculovirus-infected insect larvae are protective in vivo. BMC Biotechnol. 2012, 12:59.
77. Vega C.G., et al. Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea. PLoS Pathog. 2013, 9:e100334.
78. Gebauer M., Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr. Opin. Chem. Biol. 2009, 13:245-255.
79. Fraile S., et al. NanoPad: an integrated platform for bacterial production of camel nanobodies aimed at detecting environmental biomarkers. Proteomics 2013, 13:2766-2775.
80. Dolk E., et al. Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo. Appl. Environ. Microbiol. 2005, 71:442-450.
81. Pellis M., et al. A bacterial-two-hybrid selection system for one-step isolation of intracellularly functional nanobodies. Arch. Biochem. Biophys. 2012, 526:114-123.
82. Yau K.Y.F., et al. Selection of hapten-specific single-domain antibodies from a non-immunized llama ribosome display library. J. Immunol. Methods 2003, 281:161-175.
83. Ryckaert S., et al. Isolation of antigen-binding camelid heavy chain antibody fragments (nanobodies) from an immune library displayed on the surface of Pichia pastoris. J. Biotechnol. 2010, 145:93-98.
84. Fleetwood F., et al. Surface display of a single-domain antibody library on Gram-positive bacteria. Cell. Mol. Life Sci. 2013, 70:1081-1093.
85. Goldman E.R., et al. Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library. Anal. Chem. 2006, 78:8245-8255.
86. Monegal A., et al. Immunological applications of single-domain llama recombinant antibodies isolated from a naive library. Protein Eng. Des. Sel. 2009, 22:273-280.
87. Even-Desrumeaux K., et al. Single-domain antibodies: a versatile and rich source of binders for breast cancer diagnostic approaches. Mol. Biosyst. 2012, 8:2385-2394.
88. Groot A.J., et al. Reverse proteomic antibody screening identifies anti adhesive VHH targeting VLA-3. Mol. Immunol. 2009, 46:2022-2028.
89. Kastelic D., et al. A single-step procedure of recombinant library construction for the selection of efficiently produced llama VH binders directed against cancer markers. J. Immunol. Methods 2009, 350:54-62.
90. Monegal A., et al. Single domain antibodies with VH hallmarks are positively selected during panning of llama (Lama glama) naive libraries. Dev. Comp. Immunol. 2012, 36:150-156.
91. Verheesen, P. and De Jonghe, C. (2013) Manufacturing of specifically targetting microcapsules. WO Patent 2,013,050,594.
92. Verheesen, P. and De Jonghe, C. (2012) Specific delivery of agrochemicals. US Patent App. 13/647,302.
93. Verheesen, P. and Jongedijk, E. (2011) Insect binding antibodies. US Patent App. 13/819,326.